(TWST) as a Liquidity Pulse for Institutional Tactics

Certain Stock Options of Twist Bioscience Corporation are subject to a Lock-Up Agreement Ending on 4-OCT-2026.

Twist Bioscience (TWST) Rallies As Growth Narrative Tests Whether The Stock Is Already Pricey

An officer's proposed sale at Twist Bioscience (TWST) includes shares to cover an equity-award tax bill.

An officer proposes selling vested shares at Twist Bioscience (TWST), partly to cover an equity-award tax obligation.

Twist Bioscience (TWST) Stock Fair Value Edges Higher As Analysts Split On AI Upside

Twist Bioscience (TWST) Stock Could Be Reasonable On Its 9x Three Year Run

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

The Top HealthTech Questions Landing On Our Desks

Leerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190

Twist Bioscience: Don't Confuse A Short Squeeze With An AI Revolution

Foundayo’s Early Growth Is Raising Lilly (LLY)’s Revenue Expectations. But Can It Outrun Pricing Pressure?

What Needs To Be True To Buy Twist Bioscience Stock Now?

Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?